Using the experimental autoimmune encephalomyelitis (EAE) model, the effect of Symadex was evaluated during both the acute and chronic phases of EAE in the mouse models. A partial, concentration-dependant decrease in clinical signs was observed in the acute prevention experiment, and chronic treatment resulted in a dose-dependent reduction of clinical scores. Plasma titers in a combined treatment group versus disease controls showed significant changes with a trend towards restoring baseline levels of biomarkers found in naïve controls.
Stephen Karlik, professor of diagnostic radiology at the University of Western Ontario, said: “The evidence that Symadex targets innate immune cell function in the treatment of multiple sclerosis is encouraging and is a foundation for the company’s continued work on Symadex in autoimmune models.”